Akesobio (康方生物) Pre-IPO: Late in the PD-1 Game but Products Are Promising
Akesobio is a clinical-stage biopharmaceutical company with a focus on developing biologics drugs for oncology and autoimmune. The company plans to...
709 Views
MSCI ACWI, STOXX 600 Breaking Out, Adding Fuel for Further U.S. Equity Market Rally
In today’s report we reiterate our bullish U.S. investment thesis, recap significant technical levels across indexes, and highlight attractive...
715 Views
Alibaba IPO/​​​​Secondary Listing Trading - Time to Converge, That's It
Alibaba Group Holding (BABA US) raised around US$13bn (including over-allocation) via a secondary listing in Hong Kong. I've covered various...
574 Views
Alibaba HK Listing: Thoughts on the Premium/Discount to the ADRs
Alibaba Group Holding (BABA US) plans to launch a $10-15 billion secondary listing in Hong Kong on 11 November, Singles Day, according to press...
1.1k Views
Shanghai Henlius Biotech IPO: Valuation Prescribed at Low-End
Shanghai Henlius Biotech (2696 HK)Â is a biopharmaceutical company and a non-wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group) (2196...
922 Views